Quintiles invests a further US$14m in China
Will also expand lab testing capabilities with SCRC
Quintiles, a fully integrated biopharmaceutical services company headquartered in Durham, NC, US, is investing US$14m to establish a regional headquarters for China in Shanghai and is also significantly expanding its laboratory testing capabilities in China.
Under a joint agreement with the full-service Shanghai Clinical Research Centre (SCRC), Quintiles will provide lab testing services to local customers.
The new 4,000m2 regional headquarters will serve China and nearby Asian countries. The office in Feng Lin Science Park is expected to accommodate more than 450 people in the next five years.
‘These investments and agreements demonstrate our commitment to the Shanghai Xuhui District People’s Government and to China,’ said Ling Zhen, general manager for Quintiles’ operations in China.
‘Quintiles recognises the unique needs of our customers in China. By collaborating with SCRC in labs we can help local and international biopharma companies develop new and better medicines to serve China’s enormous unmet medical needs.’
Rongxing Gan, president of SCRC, said: ‘SCRC’s Central Laboratory’s experienced staff and modern technology will be further enhanced through Quintiles’ investments. We are delighted to work closely with Quintiles to further biopharma innovation and improve human health.’
The Quintiles-SCRC collaboration follows last year’s launch of Kun Tuo, Quintiles’ local contract research organisation, built to help local and global biopharma companies achieve successful registration of medicines in China.
Quintiles commenced operations in China in 1997, and today has offices in Beijing, Dalian, Hong Kong and Shanghai, with employees and capabilities to serve all major population centres and study sites across China.
